

Stella Stergiopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/893918/publications.pdf>

Version: 2024-02-01

20
papers

303
citations

932766

10
h-index

940134

16
g-index

21
all docs

21
docs citations

21
times ranked

329
citing authors

#	ARTICLE	IF	CITATIONS
1	A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals. <i>Drug Safety</i> , 2016, 39, 1117-1127.	1.4	39
2	The Impact of Protocol Amendments on Clinical Trial Performance and Cost. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 436-441.	0.8	37
3	Evaluating the Completeness and Accuracy of MedWatch Data. <i>American Journal of Therapeutics</i> , 2014, 21, 442-446.	0.5	34
4	Quantifying the Magnitude and Cost of Collecting Extraneous Protocol Data. <i>American Journal of Therapeutics</i> , 2015, 22, 117-124.	0.5	32
5	Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 103-116.	0.8	30
6	Evaluating the Completeness of ClinicalTrials.gov. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 307-317.	0.8	22
7	Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development. <i>Therapeutic Innovation and Regulatory Science</i> , 0, , 216847901881751.	0.8	20
8	Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey. <i>Pharmaceutical Medicine</i> , 2019, 33, 499-510.	1.0	15
9	Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial. <i>Clinical Infectious Diseases</i> , 2018, 66, 72-80.	2.9	13
10	Assessing Patient Participation Burden Based on Protocol Design Characteristics. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, , 216847901986728.	0.8	11
11	Regulatory Definitions and Good Pharmacovigilance Practices in Social Media: Challenges and Recommendations. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 840-851.	0.8	10
12	New Governance Mechanisms to Optimize Protocol Design. <i>Therapeutic Innovation and Regulatory Science</i> , 2013, 47, 651-655.	0.8	9
13	Identifying and Quantifying the Accuracy of Product Name Attribution of US-Sourced Adverse Event Reports in MedWatch of Somatropins and Insulins. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 706-716.	0.8	6
14	Baseline Assessment of a Global Clinical Investigator Landscape Poised for Structural Change. <i>Therapeutic Innovation and Regulatory Science</i> , 2017, 51, 575-581.	0.8	5
15	#PatientVoiceMatters: How Social Media Is Bringing Patients and Biopharmaceutical Companies Together to Improve Drug Development. <i>Clinical Therapeutics</i> , 2017, 39, 2170-2172.	1.1	5
16	Mobile Nurse Services in Clinical Trials: Usage and Industry Perceptions. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 442-449.	0.8	4
17	Shingles vaccination uptake in Massachusetts adults aged 50 years and older. <i>Vaccine</i> , 2021, 39, 6781-6786.	1.7	4
18	Assessing Patient Participation Burden Based on Protocol Design Characteristics. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 598-604.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices. <i>Drug Safety</i> , 2015, 38, 687-692.	1.4	2
20	Mapping and Characterizing the Development Pathway from Non-Clinical through Early Clinical Drug Development. <i>Pharmaceutical Medicine</i> , 2012, 26, 297-307.	1.0	1